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Phase II Studies of Docetaxel in the Treatment of 
Various Solid Tumours
J. Verweij, G. Catimel, A. Sulkes, C. Sternberg, I. Wolff, S. Aamdal and 
Q. van Hoesel on behalf of the EORTC Early Clinical Trials Group and the 
EORTC Soft Tissue and Bone Sarcoma Group
Docetaxel has been evaluated in six tumour types in a total of 189 patients entered into phase II studies. Treatment 
consisted of a I h intravenous infusion of docetaxel 100 mg/m2 repeated every 3 weeks. No premedication was 
administered for possible hypersensitivity reactions. Docetaxel was found to be effective as first-line chemo­
therapy for head and neck cancer (response rate 44%) gastric cancer (23%) and melanoma (14%) and as second- 
line chemotherapy for soft tissue sarcomas (21%; 95% confidence interval: 7.5%-43.7%). The results in colorectal 
and renal cancer were disappointing, with response rates of less than 10%. The most frequent adverse 
effects were alopecia (81%), grade III-IV leucocytopenia of short duration (66%) and skin reactions (52%). 
Hypersensitivity reactions were mild and occurred in 26% of patients. Docetaxel is an important new drug in the 
treatment of solid tumours.
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INTRODUCTION
T he num ber  of cytotoxic drugs which are effective in the 
treatment of solid tumours is still fairly limited. Drug develop­
ment in the last decade has focused on new classes of compounds, 
including the taxoid derivatives, which have unique mechanisms 
of action. Docetaxel (Taxotere®) is a semisynthetic taxoid 
derived from the needles of the European yew, Taxus baccata L. 
During pharmacological screening it exhibited very promising 
activity in solid tumours, both in vitro and in vivo. The main 
adverse effects reported from phase I studies were granulocyto­
penia of short duration, general alopecia and mucositis. Hyper­
sensitivity reactions (HSRs) were mild and infrequent.
Based on the findings from phase I clinical trials, the most 
appropriate regimen for phase II assessment appeared to be a
I h intravenous (i.v.) infusion of docetaxel 100 mg/m2 repeated 
every 3 weeks. This dosage regimen resulted in the best balance 
between clinical efficacy and overall tolerability, and was associ­
ated with the lowest incidence of mucositis, which was important 
in view of the concomitant granulocytopenia. A large scale phase
II study programme in solid tumours was initiated in 1991.
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Phase II studies with docetaxel have been performed or are 
ongoing in the following tumour types: as first-line chemo­
therapy for squamous ceil head-and-neck cancer [1], gastric 
cancer [2], pancreatic and colorectal cancer [3], renal cancer [4], 
bladder cancer and malignant melanoma [5] and as first and 
second-line chemotherapy for soft tissue sarcomas [6], The 
results in breast, ovarian and lung cancers are discussed else­
where [7-12].
PATIENTS AND METHODS
Patients included in the phase II studies discussed in this 
report had bidimensionally measurable locally advanced or 
metastatic cancers [1-6]. Where demographic data were pro­
vided, the median age of the patients ranged from 54 to 63 
years and the median WHO performance status was 1 (0-2) 
[1, 3, 4, 6]. Docetaxel 100 mg/m2 was administered as a 1 h i.v, 
infusion every 3 weeks. Docetaxel was supplied in 2 ml vials as 
a 40 mg/ml sterile solution in polysorbate 80. Immediately prior 
to use, the solution was diluted according to specific instructions. 
The correct individual dosage was withdrawn and further diluted 
in either dextrose 5% or saline 0.9%, and administered by i.v. 
infusion over 1 h. Patients received a median of two cycles.
In view of the results of phase I studies, neither anti-emetic 
agents nor prophylactic measures to prevent HSRs were rou­
tinely prescribed. However, if HSRs occurred during drug 
infusion, the infusion was interrupted and 5-10 mg of dexame- 
thasone and an antihistamine were administered, after which the 
infusion was restarted [1-6]. In the event of delayed HSRs, 
symptomatic treatment was left to the discretion of the treating 
physician. Prophylactic measures in subsequent courses of ther-
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apy were optional for patients who experienced mild to moderate 
HSRs to docetaxel; for patients who experienced severe HSRs, 
subsequent courses of docetaxel were preceded by a combination 
of dexamethasone and an antihistamine.
All studies used a common schedule for dose reduction when 
other types of adverse effects occurred. In general, the dose was 
reduced by 25% if grade IV granulocytopenia lasted >7 days or 
if it coincided with fever of ^38.5°C. Provisions were also made 
for dosage reduction in the event of skin reactions, mucositis 
and other side-effects. After any dose reduction, re-escalation 
for subsequent cycles was not permitted.
RESULTS
Antitumour activity 
The broad spectrum antitumour activity of docetaxel observed 
in vitro and in vivo appears to be translated into clinical efficacy, 
as shown by preliminary data from phase II trials (Table 1) 
[1-6], The only tumour types with a reported response rate of 
<10% were colorectal and renal cancer [3,4], reconfirming 
the insensitivity of these tumour types to currently available 
cytotoxic drugs. Docetaxel has demonstrated activity in all other 
tumour types studied to date. Studies in pancreatic cancer and 
bladder cancer are still ongoing, but responses have been 
observed in both tumour types. The reported response rates in 
head and neck cancer, gastric cancer, melanoma and soft tissue 
sarcoma must be interpreted cautiously because the studies have 
only been published in abstract form, and not all the patients 
have been evaluated. Nevertheless, it is clear that encouraging 
data are emerging.
Head and neck cancer 
The response rate to docetaxel in squamous cell head and neck 
cancer is unprecedented compared with results obtained with 
other antineoplastic agents [1, 13]. More than 50% of the 
patients in the study conducted by the EORTC Early Clinical 
Trials Group had received prior radiotherapy and 8 patients had 
received prior neoadjuvant chemotherapy. More than half of the 
patients had either regional or distant metastases, or both* In 
this scenario, the 11 responses in 25 evaluated padents reflect 
impressive antitumour activity. This tumour type may be parti­
cularly susceptible to treatment with docetaxel, and the data 
justify a confirmatory study and an evaluation of combination 
chemotherapeutic regimens incorporating docetaxel.
Gastric cancer
In 26 patients with metastatic gastric cancer who had not 
received previous chemotherapy, 6 partial remissions (23%) 
have been reported [2]. The response rates to individual agents 
used to treat gastric cancer vary from 20 to 30%; therefore, 
docetaxel can be considered to be active in this disease [ 14]. In 
addition, the value of currently used combinations of active 
agents in gastric cancer is being questioned, since survival after 
single agent 5-fluorouracil treatment was similar to survival after 
combination chemotherapy in a recently reported, randomised 
study [15]. These encouraging results with docetaxel suggest that 
its use in combination regimens with other chemotherapeutic 
agents may improve current response rates.
M  elanomas
Metastatic malignant melanoma is a very difficult disease to 
treat. There is still no widely accepted standard chemotherapy 
treatment, and reported response rates are usually low. Dacarba- 
zine is considered by many specialists to be the standard 
treatment, with an overall response rate of approximately 15%. 
However, this is the cumulative result from a wide variety of 
studies with response rates ranging from 0 to 30%. In compari­
son, the 14% response rate presently reported for docetaxel in 
this disease is favourable [5]. In view of the heterogeneous 
response to dacarbazine, as well as the unpredictability of 
response duration, there is an incentive for extending the 
experience with single agent docetaxel and for assessing its 
efficacy in combination with other drugs active against malignant 
melanomas.
Soft tissue sarcoma
Soft tissue sarcomas are rare and, like melanomas, difficult to 
treat once metastasised. Only three cytotoxic drugs presently 
available, doxorubicin, dacarbazine, and ifosfamide, yield a 
response rate of >  15% [16]. Therefore, the results obtained with 
docetaxel by the EORTC Soft Tissue and Bone Sarcoma Group 
are of particular interest [6]. In 23 evaluated patients who had 
inadequate response to prior chemotherapy, the response rate 
was 22%. Of particular note, one additional patient showed a 
mixed response, a status never before observed in soft tissue 
sarcomas, The National Cancer Institute of Canada recently 
started a study in patients with this disease who have not received 
previous chemotherapy. In view of the limited drug treatment
Table 1 . Antitumour activity of docetaxel in phase I I  trials
•
Tumour type Previous treatment No. of Response rate
(reference) (No. of enrolled patients) patients (%)
evaluated (95% Cl)
Head and neck cancer [1] Radiotherapy (22) 25 44 (24-65%)
Neoadjuvant chemotherapy (8)
Gastric cancer [2] None 26 23 (9-44%)
Colorectal cancer [3] Radiotherapy (8) 29 3 (0-18%)
Chemotherapy (4)
Renal cancer [4] No prior chemotherapy 51 4 (0-10%)
Melanoma [5] No prior chemotherapy 35 14 (5-30%)
Soft tissue sarcoma [6] 1 prior combination chemotherapy or two single 23 22 (7—47%)
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options for this disease, investigating the role of docetaxel in 
combination chemotherapy is warranted.
Adverse events
Many hundreds of patients with different tumour types have 
now been treated with docetaxel 100 mg/m2 as a 1 h i.v. infusion 
every 3 weeks. Adverse effects reported most frequently in 
studies published to date are listed in Table 2 [1-12].
Alopecia is a common adverse effect and is usually universal. 
It occurs 2-4 weeks after the initiation of docetaxel and is fully 
reversible after treatment discontinuation.
Leucopenia and granulocytopenia may also occur with doce­
taxel at this dosage and schedule; the incidence of grade IV 
leucopenia/granulocytopenia is over 60%. The onset is quite 
early, with the nadir occurring between days 5 and 8, followed 
by a very rapid recovery. Dosage delays for persisting myelo- 
suppression are very rarely required. The short duration of 
leucopenia and granulocytopenia is also reflected in the number 
of concomitant infections, which is low in relation to the 
severity of myelosuppression. Thrombocytopenia is infrequent 
and rarely severe.
HSRs with docetaxel appear to be less frequent than with 
other taxoids and are generally mild. The vast majority of HSRs 
occur during the first two cycles of docetaxel and always within 
minutes of starting the infusion [17]. The overall incidence is 
approximately 25% [17-19]. In patients receiving further cycles 
without prophylactic measures, the incidence of subsequent 
HSRs is approximately 30% [17]. Premedication with cortico­
steroids reduces the incidence of HSRs to a level where they can 
no longer be considered a major clinical problem.
Docetaxel is occasionally associated with skin reactions, 
including erythema, desquamation and, infrequently, exfoli­
ation. Nail changes consisting of calcification and onycholysis, 
which may at times be quite painful, have also been observed. 
The dermatitic lesions are always reversible, usually after 21 
days, and there is some evidence suggesting that premedication 
with cortisosteroids is preventative. Hail changes appear to be 
related to cumulative dose rather than dose per course, since 
they do not occur after the first or second courses. Premedication 
with corticosteroids does not seem to prevent this effect, but it 
is reversible after treatment is stopped [18].
Nausea and/or vomiting are still the most distressing adverse
Table 2. Adverse effects o f docetaxel in phase II  studies in patients
with solid tumours
Adverse effect Incidence 
(% of patients)
Alopecia 81
Grade IV leucocytopenia 66
Cutaneous effects 52
Nausea/vomiting 46
Diarrhoea 40
Mucositis 34
Arthralgia/myalgia 27
Hypersensitivity 26
Infections 21
Fluid retention 18
Fever 17
Constipation 12
Headache 11
Cardiotoxicity 0
effects of other forms of chemotherapy [20], but they are 
relatively infrequent with docetaxel and easily counteracted with 
prophylactic use of conventional anti-emetics during subsequent 
courses. The routine use of 5HT3 antagonists is not necessary 
when administering single agent docetaxel.
Fluid retention, which appears to be related to the cumulative 
dose of docetaxel, is an unusual adverse effect which is generally 
observed peripherally, but may occur at other sites; pleural 
effusions and ascites have also been reported. At cumulative 
doses of <400 mg/m2, this side effect is infrequent, but the 
incidence rapidly increases at doses of sMOO mg/m2 [18], 
Corticosteroid premedication may also reduce the incidence of 
this adverse event [18, 19], but prospective studies are needed 
before definitive conclusions can be made.
Arthralgia and myalgia, which have been reported during 
treatment with docetaxel, usually occurred after a few days and 
disappeared rapidly. In general, the effects are mild and respond 
to simple analgesics although they may occasionally be trouble­
some for the patient.
Peripheral neuropathy has rarely been reported and was 
always mild. Cardiac rhythm disturbances or cardiac function 
abnormalities have not been reported.
CONCLUSION
Docetaxel is a cytotoxic drug with antitumour activity in a 
wide range of cancers. These studies have provided evidence of 
the activity of docetaxel as first-line therapy in head and neck 
cancer, gastric cancer and melanoma and as second-line therapy 
in soft tissue sarcoma. It must be noted, however, that because 
these studies have been published in abstract form only, the 
results must be considered preliminary until verified by peer 
review.
Future phase II studies should examine the efficacy of doce­
taxel in tumour types that have not yet been studied and in 
combination chemotherapy regimens. Finally, as in the past 
with drugs like cisplatin, doxorubicin, and bleomycin, methods 
of circumventing the adverse effects associated with docetaxel 
must be found.
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